En undersøgelse udført med pædiatriske patienter (4- 16 år) med anfald af partiel type viste at 55, 4% af patienterne i Keppragruppen og 40, 2% af patientererne i placebogruppen oplevede bivirkninger.
A study conducted in paediatric patients (4 to 16 years) with partial onset seizures showed that 55.4% of the patients in the Keppra group and 40.2% of the patients in the placebo group experienced undesirable effects.